TRANSLATE

Welcome to Our Parkinson's Place


I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please No advertisers, and No Information about Herbal treatments. This is a free site for all.
Thank you.


Wednesday, May 10, 2017

International Stem Cell’s Trial in Parkinson’s Can Continue, Board Says

MAY 10, 2017  BY DANIELA SEMEDO, PHD

International Stem Cell’s clinical trial testing its ISC-hpNSC neural cells for the treatment of Parkinson’s disease (PD) can move forward, the company said.
The announcement comes after an evaluation from experts from a Data Safety Monitoring Board (DSMB), who looked at the safety data from the first group of patients enrolled in the trial.
The DSMB said the study can continue with accelerated enrollment and a dose escalation in a second group of patients. The company is now recruiting the second cohort of Parkinson’s patients, who will be receiving a higher dose of 50,000,000 of ISC-hpNSC neural cells.
The open-label, single center, uncontrolled Phase 1 trial (NCT02452723) expects to recruit 12 patients with moderate Parkinson’s. Patients are divided into three groups of four patients each. The groups are receiving increasing doses ranging from 30,000,000 to 70,000,000 neural stem cells transplanted intracranially. The main goal of the trial is to assess the safety of the treatment, with patients followed for 12 months after the transplants.
All patients undergo a positron emission tomography (PET) scan when they enter the study, and then at six and 12 months after surgical intervention. The clinical responses of participants compared to baseline after the administration of ISC-hpNSC are evaluated using the Unified Parkinson Disease Rating Scale (UPDRS) and other tools.
Last month, the company said that the fourth and last patient with Parkinson’s of the first group had successfully received the neural stem cell transplant. To date, trial investigators have not recorded any adverse events among the four patients who had the stem cells inserted into their brains.
“The DSMB approval represents an important step in the clinical development of ISC-hpNSC,” Andrey Semechkin, co-chairman and CEO of the company, said in a recent press release. “In the second cohort we will begin to evaluate the higher cell dose that we believe will have the most likely favorable outcomes and potential to benefit patients.”
ISC-hpNSC cells are derived from unfertilized human eggs, so while they retain all the advantages of embryonic cells, they cannot generate a human being. In this manner, these cells are safe from any ethical issues associated with the use or destruction of viable human embryos.
https://parkinsonsnewstoday.com/2017/05/10/international-stem-cells-trial-in-parkinsons-disease-can-continue-board-says/

No comments:

Post a Comment